Lopinavir, Drugs Monitor

(23 Apr 2021) Hydroxychloroquine, Lopinavi/R- no significant benefit for decreasing COVID-19-associated hospitalization

April 30, 2021

Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial https://doi.org/10.1001/jamanetworkopen.2021.6468 NCT04403100- Of 685 participants, 632 (92.3%) self-identified as mixed-race, 377 (55.0%) were women, and the median… Continue reading "(23 Apr 2021) Hydroxychloroquine, Lopinavi/R- no significant benefit for decreasing COVID-19-associated hospitalization"

(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19

October 17, 2020

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1 The interim results from Solidarity trials (ISRCTN83971151 , NCT04315948 ) are presented. In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon… Continue reading "(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19"

(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19

June 13, 2020

Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. https://doi.org/10.1101/2020.06.05.20123299 The aim of this retrospective intent-to-treat analysis of the hospitalized patients was to compare the rate of clinical improvement between… Continue reading "(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19"

(08 May 2020) Clinical trial findings- early triple antiviral combination effective

May 9, 2020

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext In a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19, shortening in… Continue reading "(08 May 2020) Clinical trial findings- early triple antiviral combination effective"

Tag: Lopinavir

(23 Apr 2021) Hydroxychloroquine, Lopinavi/R- no significant benefit for decreasing COVID-19-associated hospitalization

(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19

(12 June 2020) Lopinavir/ritonavir- No significant benefit of combined LPV/r and HCQ treatment of COVID-19

(08 May 2020) Clinical trial findings- early triple antiviral combination effective